Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients

by Vandana Singh, Benzinga Editor

August 2, 2021 12:40 PM | 1 min read | Make a Comment

The FDA has signed off Sorrento Therapeutics Inc's SRNE IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR)-T Cell therapy for relapsed or refractory multiple myeloma.
DAR-T technology is readily adaptable to dozens of cancer targets, and Sorrento has developed a preclinical product pipeline with specific fully human antibodies discovered from Sorrento's G-MAB library.
Sorrento expects to file additional IND applications now that the first DAR-T Phase 1 trial has been cleared to proceed by the FDA.
Price Action: SRNE shares are up 2.98% at $8.47 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar

Posted In: Biotech Long Ideas News Health Care FDA Trading Ideas General Briefs multiple myeloma

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.